Clinical Trial Update: Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neratinib with or without fulvestrant in metastatic HER2 non-amplified but HER2-mutant breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• neratinib (neratinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2022-04-15